Sequence information
DRAVP ID DRAVPc001
Name Brilacidin
Sequence Not available
Molecular Formula C40H50F6N14O6
Condition/Disease COVID-19
Group Phase Ⅱ clinical trial
Type small molecule mimetic of defensin
Description Brilacidin is a synthetic, nonpeptidic, small molecule mimetic of defensin, a type of host defense proteins/peptides (HDPs) or antimicrobial peptides (AMPs), with potential antibacterial and antiviral activities. Upon administration, brilacidin selectively destabilizes bacterial and viral membrane integrity, which leads to their proteolysis and degradation. HDPs are part of the innate immune response and act as the first line of defense against foreign pathogens. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been shown to suppress defensins.
Active sequence/Structure
External Links
DrugBank Accession Number DB12997
Pubchem ID 25023695
CHEMBL ID CHEMBL2219413
UNII I1679X069H
CAS 1224095-98-0
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT04784897 | A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 | COVID-19 | Completed | Phase 2 | Innovation Pharmaceuticals, Inc. |
